ArticleSurgery in practice and science2025
Chemo-radiotherapy after neoadjuvant chemotherapy and radical hysterectomy in women with stage IB-IIB cervical cancer: Do we need to change the therapeutic approach? A cohort study.
Article in Surgery in practice and science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Construction and validation of the prediction model for fear of cancer recurrence in patients with postoperative cervical cancer.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemoradiotherapy is recommended as the standard treatment for advanced cervical cancer, and neoadjuvant chemotherapy (NACT) can be beneficial for patients on long radiotherapy waiting lists. This study aimed to evaluate the need for chemoradiotherapy after NACT and radical hysterectomy in women with stage IB-IIB cervical cancer. Methods: This was a retrospective, cohort study. All patients in the gynecologic oncology clinic of Imam Khomeini Hospital, Tehran, Iran, who were diagnosed with stage IB-IIB cervical cancer and treated with NACT and radical hysterectomy between 2010 and 2020, were included in this study. The records of all the patients who met the inclusion criteria were evaluated during the study period. Outcomes of interest and progression-free survival (PFS) were also assessed. Results: In this study, the clinical files of 613 patients with cervical cancer were studied, and among them, 63 patients (10.2%) underwent NACT. Eighteen patients (33.3%) did not require another treatment modality after chemotherapy and radical hysterectomy, while 66.7% (36 cases) of patients required chemoradiotherapy after NACT and radical hysterectomy, and recurrence was observed in 11.6% (5 cases) of patients. The 1-, 5- and 10-year PFS rate was 97.6% (95% CI: 84.2-99.6), 89.5% (95% CI: 74.4-95.9) and 89.5% (95% CI: 74.4-95.9), respectively. Conclusions: It can be concluded that a significant percentage of patients who are candidates for NACT followed by radical hysterectomy would require another modality of treatment, which is chemoradiotherapy; therefore, it is recommended that by conducting prospective studies, in addition to investigating this issue, the choice of the first method of patient treatment in these stages should be reconsidered so that patients do not suffer from two treatments and related complications, and undergo chemoradiotherapy from the beginning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.